ETHICAL CONSIDERATIONS OF THE USE OF INVESTIGATIONAL NEW DRUGS DURING THE GULF WAR

At the onset of the Gulf War in 1992, the threat of chemical and biological weapons prompted the Department of Defense to seek a waiver from the Food and Drug Administration to use the investigational new drugs pyridostigmine bromide and botulism vaccine without first obtaining consent from those servicemen and women who would receive the drugs. The waiver was granted and came in the form of the Interim Rule, which permitted the use of investigational new drugs when consent could not be obtained because of "non-feasibility" and the nature of the military mission. The Interim Rule restricted the soldiers' rights to informed consent, but was it justified?

Grantor dc:publisher

Wake Forest University

Year dc:date.issued

2011

Author dc:creator

• Ghaffar, Sajid

• Gulf War

Language dc:language.iso

en

Handle dc:identifier.uri

http://hdl.handle.net/10339/36150

OAI identifier oai:identifier

oai:wakespace.lib.wfu.edu:10339/36150